| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Amy Patel | Q91789194 |
| P2093 | author name string | Yao Wang | |
| Raymond S Douglas | |||
| P2860 | cites work | Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy | Q74010201 |
| Thyrotropin receptor expression in Graves' orbital adipose/connective tissues: potential autoantigen in Graves' ophthalmopathy | Q74324679 | ||
| A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves' ophthalmopathy | Q74459180 | ||
| Slow-release lanreotide in Graves' ophthalmopathy: A double-blind randomized, placebo-controlled clinical trial | Q79775301 | ||
| Full-thickeness anterior blepharotomy and transpalpebral fat decompression in Graves' orbitopathy | Q81282886 | ||
| Development and course of exophthalmos and ophthalmoplegia in Graves' disease with special reference to the effect of thyroidectomy | Q82104621 | ||
| Thyroid eye disease | Q83446693 | ||
| CD8+CD28-lymphocytes in peripheral blood and serum concentrations of soluble interleukin 6 receptor are increased in patients with Graves' orbitopathy and correlate with disease activity | Q83847859 | ||
| Eyebrow tissue expansion: an underappreciated entity in thyroid-associated orbitopathy | Q85643449 | ||
| Smoking induces overexpression of immediate early genes in active Graves' ophthalmopathy | Q87611745 | ||
| Teprotumumab, an insulin-like growth factor-1 receptor antagonist antibody, in the treatment of active thyroid eye disease: a focus on proptosis | Q90695307 | ||
| Efficacy of Tocilizumab in Patients With Moderate-to-Severe Corticosteroid-Resistant Graves Orbitopathy: A Randomized Clinical Trial | Q90775985 | ||
| Current and Emerging Treatment Strategies for Graves' Orbitopathy | Q91118565 | ||
| Tocilizumab for thyroid eye disease | Q93333216 | ||
| Rituximab for thyroid-associated ophthalmopathy | Q24202845 | ||
| Graves' Ophthalmopathy: VISA versus EUGOGO Classification, Assessment, and Management | Q26782424 | ||
| Acute thyroid eye disease (TED): principles of medical and surgical management | Q26827429 | ||
| Selenium and the course of mild Graves' orbitopathy | Q28238021 | ||
| Clinical features of Graves' ophthalmopathy in an incidence cohort | Q28275743 | ||
| Graves' Disease. | Q30243909 | ||
| Prospective, systematically recorded mycophenolate safety data in Graves' orbitopathy | Q31047067 | ||
| Clinical characteristics of moderate-to-severe thyroid associated ophthalmopathy in 354 Chinese cases | Q33637524 | ||
| Management of Graves' ophthalmopathy: reality and perspectives | Q33899550 | ||
| Thyroid-associated orbitopathy | Q33910021 | ||
| Teprotumumab, an IGF-1R blocking monoclonal antibody inhibits TSH and IGF-1 action in fibrocytes. | Q34130987 | ||
| The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota | Q34164149 | ||
| Rundle and his curve | Q34170719 | ||
| Teprotumumab for Thyroid-Associated Ophthalmopathy. | Q34556184 | ||
| Quality of life in patients with Graves ophthalmopathy. | Q34565430 | ||
| Cytokines are both villains and potential therapeutic targets in thyroid-associated ophthalmopathy: From bench to bedside. | Q34763844 | ||
| Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study. | Q35055076 | ||
| Randomized controlled trial of rituximab in patients with Graves' orbitopathy | Q35055124 | ||
| Bidirectional TSH and IGF-1 receptor cross talk mediates stimulation of hyaluronan secretion by Graves' disease immunoglobins | Q35096870 | ||
| Impact of smoking on the response to treatment of thyroid associated ophthalmopathy | Q35591093 | ||
| Assessing quality of life in Australian patients with Graves' ophthalmopathy | Q35591594 | ||
| Treatment of thyroid associated ophthalmopathy with periocular injections of triamcinolone | Q35592595 | ||
| Late reactivation of thyroid orbitopathy | Q35640355 | ||
| Risk factors for development or deterioration of Graves' ophthalmopathy | Q35975724 | ||
| Clinical features of dysthyroid optic neuropathy: a European Group on Graves' Orbitopathy (EUGOGO) survey | Q36014781 | ||
| The pathophysiology of thyroid eye disease: implications for immunotherapy. | Q36439938 | ||
| Prominent premalar and cheek swelling: a sign of thyroid-associated orbitopathy | Q36658850 | ||
| The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy | Q36811289 | ||
| B cells from patients with Graves' disease aberrantly express the IGF-1 receptor: implications for disease pathogenesis. | Q36924505 | ||
| Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves' orbitopathy. | Q37017174 | ||
| Ciclosporin and prednisone v. prednisone in treatment of Graves' ophthalmopathy: a controlled, randomized and prospective study | Q70321449 | ||
| Autoantibodies to IGF-1 binding sites in thyroid associated ophthalmopathy | Q71632265 | ||
| Randomized trial of intravenous immunoglobulins versus prednisolone in Graves' ophthalmopathy | Q71778725 | ||
| Randomized double-blind trial of prednisone versus radiotherapy in Graves' ophthalmopathy | Q72235149 | ||
| Graves' ophthalmopathy in the absence of elevated free thyroxine and triiodothyronine levels: prevalence, natural history, and thyrotropin receptor antibody levels | Q73496914 | ||
| Superoxide radical production stimulates retroocular fibroblast proliferation in Graves' ophthalmopathy | Q73618559 | ||
| Radiotherapy for Graves' orbitopathy: randomised placebo-controlled study | Q73761107 | ||
| Visual field defects in exophthalmos associated with thyroid disease | Q73839439 | ||
| Antioxidant agents in the treatment of Graves' ophthalmopathy | Q73870904 | ||
| Psychosocial morbidity of Graves' orbitopathy. | Q51925700 | ||
| Efficacy and safety of mycophenolate mofetil in patients with active moderate-to-severe Graves' orbitopathy. | Q53057871 | ||
| A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves' ophthalmopathy. | Q53359335 | ||
| Reactivation of Graves' orbitopathy after rehabilitative orbital decompression. | Q53497830 | ||
| Thyroid-associated Ophthalmopathy. | Q53743982 | ||
| New advances in understanding thyroid-associated ophthalmopathy and the potential role for insulin-like growth factor-I receptor. | Q55024151 | ||
| Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. | Q55049410 | ||
| Efficacy and Safety of Three Different Cumulative Doses of Intravenous Methylprednisolone for Moderate to Severe and Active Graves' Orbitopathy | Q58109526 | ||
| Serial TSH-receptor antibody levels to guide the management of thyroid eye disease: the impact of smoking, immunosuppression, radio-iodine, and thyroidectomy | Q58606862 | ||
| Infliximab: A Novel Treatment for Sight-Threatening Thyroid Associated Ophthalmopathy | Q60207430 | ||
| Severe unilateral orbitopathy in a patient with Hashimoto's thyroiditis - a case report | Q60915679 | ||
| Orbital Radiotherapy Plus Concomitant Steroids in Moderate-to-Severe Graves' Ophthalmopathy: Good Results After Long-Term Follow-Up | Q64248548 | ||
| Dysthyroid optic neuropathy. Clinical profile and rationale for management | Q67350313 | ||
| Orbital radiotherapy combined with high dose systemic glucocorticoids for Graves' ophthalmopathy is more effective than radiotherapy alone: results of a prospective randomized study | Q67876001 | ||
| Dysthyroid optic neuropathy. The crowded orbital apex syndrome | Q68005382 | ||
| Treatment of dysthyroid lower lid retraction with autogenous tarsus transplants | Q68083517 | ||
| Ciamexone in endocrine orbitopathy. A randomized double-blind, placebo-controlled study | Q68713051 | ||
| Azathioprine in the treatment of thyroid-associated ophthalmopathy | Q68713064 | ||
| Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy | Q69288448 | ||
| Orbital Cobalt Irradiation Combined with Systemic Corticosteroids for Graves' Ophthalmopathy: Comparison with Systemic Corticosteroids Alone* | Q70251349 | ||
| The surgical management of thyroid-related upper eyelid retraction | Q70318726 | ||
| Orbital radiation for graves ophthalmopathy: a report by the American Academy of Ophthalmology | Q37033302 | ||
| Treatment of lower eyelid retraction by retractor release and posterior lamellar grafting: an analysis of 659 eyelids in 400 patients | Q37180701 | ||
| Update on thyroid eye disease and management. | Q37406589 | ||
| Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves' disease. | Q37417167 | ||
| Building the Case for Insulin-Like Growth Factor Receptor-I Involvement in Thyroid-Associated Ophthalmopathy. | Q37550127 | ||
| Orbital decompression in thyroid eye disease | Q37556318 | ||
| Clinical review: Intravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity | Q37829150 | ||
| Thyroid eye disease: towards an evidence base for treatment in the 21st century | Q37987063 | ||
| Efficacy and safety of orbital radiotherapy for graves' orbitopathy | Q38042043 | ||
| Nonsurgical management of diplopia after orbital decompression surgery | Q38045887 | ||
| Recurrent Thyroid Eye Disease | Q38332625 | ||
| Thyroid Eye Disease: Optic Neuropathy and Orbital Decompression | Q38655641 | ||
| Graves' orbitopathy as a rare disease in Europe: a European Group on Graves' Orbitopathy (EUGOGO) position statement. | Q38692635 | ||
| Graves Lower Eyelid Retraction | Q38702615 | ||
| Smoking and Eye Pathologies. A Systemic Review. Part II. Retina Diseases, Uveitis, Optic Neuropathies, Thyroid-Associated Orbitopathy | Q39082068 | ||
| TSHR as a therapeutic target in Graves' disease | Q39106190 | ||
| Adalimumab as steroid-sparing treatment of inflammatory-stage thyroid eye disease | Q39167512 | ||
| Postoperative Changes in Strabismus, Ductions, Exophthalmometry, and Eyelid Retraction After Orbital Decompression for Thyroid Orbitopathy | Q39528775 | ||
| Immunosuppressant therapy of thyroid eye disease | Q39568202 | ||
| PREGO (presentation of Graves' orbitopathy) study: changes in referral patterns to European Group On Graves' Orbitopathy (EUGOGO) centres over the period from 2000 to 2012. | Q40962257 | ||
| Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study | Q43705603 | ||
| Lid retraction and levator aponeurosis defects in Graves' eye disease. | Q43754016 | ||
| Igs from patients with Graves' disease induce the expression of T cell chemoattractants in their fibroblasts | Q43845891 | ||
| Aberrant expression of the insulin-like growth factor-1 receptor by T cells from patients with Graves' disease may carry functional consequences for disease pathogenesis. | Q44256446 | ||
| High-dose intravenous immunoglobulin treatment in Graves' ophthalmopathy | Q44504847 | ||
| Immunoglobulins from patients with Graves' disease induce hyaluronan synthesis in their orbital fibroblasts through the self-antigen, insulin-like growth factor-I receptor. | Q45096631 | ||
| Octreotide (long-acting release formulation) treatment in patients with graves' orbitopathy: clinical results of a four-month, randomized, placebo-controlled, double-blind study | Q45161391 | ||
| Double-blind, placebo-controlled trial of octreotide long-acting repeatable (LAR) in thyroid-associated ophthalmopathy. | Q45173583 | ||
| Reactivation of thyroid-associated orbitopathy after cataract surgery. | Q46069886 | ||
| Combined orbital irradiation and systemic steroids compared with systemic steroids alone in the management of moderate-to-severe Graves' ophthalmopathy: a preliminary study. | Q46748284 | ||
| Methylprednisolone pulse therapy for patients with moderately severe Graves' orbitopathy: a prospective, randomized, placebo-controlled study | Q46784134 | ||
| Tocilizumab as a steroid sparing agent for the treatment of Graves' orbitopathy | Q47160950 | ||
| IGF-I receptor and thyroid-associated ophthalmopathy | Q47259453 | ||
| Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial. | Q49360067 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | eye disease | Q3041498 |
| P304 | page(s) | 1305-1318 | |
| P577 | publication date | 2019-11-11 | |
| P1433 | published in | Therapeutics and Clinical Risk Management | Q15766913 |
| P1476 | title | Thyroid Eye Disease: How A Novel Therapy May Change The Treatment Paradigm | |
| P478 | volume | 15 |
Search more.